Following Clinical Trial Plagued with Safety, Efficacy Failures, FDA Wisely Rejects Ecstasy-based Drug
(WASHINGTON, DC) – Foundation for Drug Policy Solutions President Dr. Kevin Sabet, a former three-time White House drug policy advisor, released the following statement today in response to the U.S. Food and Drug Administration (FDA) rejecting an ecstasy-based drug, also known as MDMA, as a treatment of post-traumatic stress disorder:
“We are thankful the FDA listened to the careful analysis of objective scientists and researchers over the hype campaign of the company Lykos, formerly known as MAPS, which was caught misrepresenting results of its trials. MAPS’s leadership, which was notably comprised of psychedelics enthusiasts, has been shrouded in allegations of misconduct for years. Approval of this drug could have led to catastrophic results for victims of trauma for whom this drug was being promoted. We hope that future efforts to approve psychedelics-based drugs will be led by science and medical experts, not by the media and addiction profiteers like Elizabeth Holmes, who is serving time for misrepresenting the results of her now-disgraced health care company, Theranos.”
###